Compositions comprising a mixture of at least one cyclodextrin, a carrier, and optionally one or more vitamins and/or nutrients to improve at least one health factor of a beehive is disclosed. Methods of improving beehive health and apparatuses including such compositions are also disclosed.

Compositions comprising a mixture of at least one cyclodextrin, a carrier, and optionally one or more vitamins and/or nutrients to improve at least one health factor of a beehive is disclosed. Methods of improving beehive health and apparatuses including such compositions are also disclosed.

The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

The invention relates to the use of low-molecular glycosidic compounds with terminal D-galactose and L-fucose in the treatment of intoxications with ricin. The identified compounds form a lectin bond with the B chain of the ricin and thereby prevent further endocytosis of the toxins. The compounds should be ingested as early as possible after incorporation of the toxin and can also be used preventively. The groups bonded to the D-galactose and L-fucose can be other saccharides (e.g. fructose), polyalcohols (e.g. sorbitol), diacyl-glycerides or flavonoids (e.g. quercetin).

Galactose-heteropolysaccharide hydrolysates such as guar gum flour can also be used. The identified compounds can be used for oral, pulmonary and systemic intoxications. They should be used in corresponding pharmaceutical forms of administration. The compounds are dosed in molar excess.

A polypeptide having epoxy group-removing catalytic activity with an amino acid sequence as set forth in SEQ ID NOs: 1-35, a nucleic acid molecule encoding the polypeptide, a nucleic acid construct comprising the nucleic acid, a pharmaceutical composition for detoxification and a food, beverage or feed composition comprising the polypeptide, and a host cell and an engineered microorganism into which the nucleic acid is introduced. Disclosed are a method for producing the polypeptide; and a method for catalyzing a reaction of removing an epoxy group of a trichothecene, a method for preventing cell poisoning or relieving cytotoxicity, a method for processing a food and beverage or feed composition, and a method for reducing or decreasing a toxin in a composition, all using the polypeptide. Further disclosed are a glutathionylated derivative, a method for evaluating the detoxification effect for a sample contaminated with a trichothecene using the glutathionylated derivative.

A polypeptide having epoxy group-removing catalytic activity with an amino acid sequence as set forth in SEQ ID NOs: 1-35, a nucleic acid molecule encoding the polypeptide, a nucleic acid construct comprising the nucleic acid, a pharmaceutical composition for detoxification and a food, beverage or feed composition comprising the polypeptide, and a host cell and an engineered microorganism into which the nucleic acid is introduced. Disclosed are a method for producing the polypeptide; and a method for catalyzing a reaction of removing an epoxy group of a trichothecene, a method for preventing cell poisoning or relieving cytotoxicity, a method for processing a food and beverage or feed composition, and a method for reducing or decreasing a toxin in a composition, all using the polypeptide. Further disclosed are a glutathionylated derivative, a method for evaluating the detoxification effect for a sample contaminated with a trichothecene using the glutathionylated derivative.

The present invention relates to the field of food and pharmaceutical products, and specifically to human milk oligosaccharide for improving resistance of organism against Staphylococcus aureus infection. In particular, the present invention relates to use of human milk oligosaccharide in preparation of a nutritional composition or medicament for prevention and/or treatment of diseases associated with Staphylococcus aureus infection in individuals, or for alleviation of discomfort associated with Staphylococcus aureus infection, or for improvement of an individual's resistance against Staphylococcus aureus infection, or for improvement of an individual's innate immunity and/or anti-aging.

The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.